Compare ERNA & TOPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERNA | TOPS |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.2M |
| IPO Year | 2021 | 2004 |
| Metric | ERNA | TOPS |
|---|---|---|
| Price | $1.97 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.5K | ★ 592.6K |
| Earning Date | 11-10-2026 | 09-16-2026 |
| Dividend Yield | N/A | ★ 279.16% |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $0.27 |
| 52 Week High | $47.25 | $7.40 |
| Indicator | ERNA | TOPS |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 22.20 |
| Support Level | $1.84 | N/A |
| Resistance Level | $2.26 | $1.29 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 34.08 | 10.24 |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.